NDA 213591 · Novartis Pharm
Tabrecta
Capmatinib Hydrochloride · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Mar 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
May 6, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
52
5 Phase 3, 6 recruiting
FAERS reports
2,366
1,429 serious, 571 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 26, 2026.
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. TABRECTA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Mechanism: Capmatinib is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. MET exon 14 skipping results in a protein with a missing regulatory domain that reduces its negative regulation leading to increased downstream MET signaling. Capmatinib inhibited cancer cell growth driven by a mutant MET variant lacking exon 14 at clinically achievable concentrations and demonstrated anti-tumor activity in murine tumor xenograft models derived from human lung tumors with either a mutation leading to MET exon 14 skipping or MET amplification. Capmatinib inhibited the...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 10, 2022 Supplement 4 · Efficacy · priority review LetterLabel
- May 6, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLabelLetterReview
2 products under this application
- TABRECTA · CAPMATINIB HYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription
- TABRECTA · CAPMATINIB HYDROCHLORIDE EQ 200MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Capmatinib" as an intervention, any sponsor and status, largest first.
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolPivotal-lookingRecruiting
Cancer Research UKAcademic, hospital or other
NCT05722886 · 825 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 2029
Drug: Alectinib; Atezolizumab and 5 more · For: Haematological Malignancy; Solid Tumour
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Bristol, United Kingdom · 27 sites in all
- Molecular Profiling of Advanced Soft-tissue SarcomasPivotal-lookingCompleted
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT03784014 · 603 participants · Start Oct 19, 2019 · Primary completion Dec 1, 2023
Drug: Nilotinib; Ceritinib and 6 more · For: Soft Tissue Sarcoma
Sites: Bordeaux, France; Dijon, France; Lille, France · 17 sites in all
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT02813135 · 472 participants (planned) · Start Aug 3, 2016 · Primary completion Feb 2031
Drug: Ribociclib; Topotecan and 22 more · For: Pediatric Cancer
Sites: Copenhagen, Denmark; Villejuif, France; Angers, France · 23 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02414139 · 373 participants · Start Jun 11, 2015 · Primary completion Apr 12, 2023
Drug: Capmatinib · For: Carcinoma, Non-Small-Cell Lung
Sites: Long Beach, California; Los Angeles, California; Orange, California · 95 sites in all
- Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03484923 · 196 participants · Start Sep 10, 2018 · Primary completion Dec 30, 2022
Drug: PDR001; LAG525 and 3 more · For: Melanoma
Sites: Los Angeles, California; San Francisco, California; Boston, Massachusetts · 30 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT02335944 · 177 participants · Start Jan 13, 2015 · Primary completion Nov 10, 2020
Drug: Capmatinib; Nazartinib · For: Non Small Cell Lung Cancer
Sites: Boston, Massachusetts; Melbourne, Australia; Edmonton, Canada · 19 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01610336 · 161 participants · Start Apr 5, 2012 · Primary completion Jun 10, 2016
Drug: INC280; Gefitinib · For: Non-small Cell Lung Cancer
Sites: Woolloongabba, Australia; East Bentleigh, Australia; Auckland, Australia · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death417
- peripheral swelling289
- fatigue262
- oedema peripheral247
- nausea241
- malignant neoplasm progression182
- dyspnoea141
- oedema134
- asthenia113
- decreased appetite98
- non-small cell lung cancer95
- joint swelling93
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 253 |
| 2021 | 642 |
| 2022 | 643 |
| 2023 | 488 |
| 2024 | 145 |
| 2025 | 129 |
| 2026 | 62 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tabrecta (Capmatinib Hydrochloride)
2024 spending
$124M
Beneficiaries
1,169
6,477 claims
Per beneficiary
$106,164
$197.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,063,605 |
| 2021 | $50,107,244 |
| 2022 | $70,283,872 |
| 2023 | $93,104,407 |
| 2024 | $124,105,409 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Wolf J, Seto T, Han JY, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J, Vioix H, Pfeiffer BM, et al. · Clin Lung Cancer 2023 · Research Support, Non-U.S. Gov't, Systematic Review
- Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.
Wolf J, Hochmair M, Han JY, et al. · Lancet Oncol 2024 · Clinical Trial, Phase II, Multicenter Study
- Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
Felip E, Metro G, Soo RA, et al. · Eur J Cancer 2024 · Clinical Trial, Phase II, Clinical Trial, Phase I
- Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open-label, single-dose, parallel-group study.
Chen X, Cui X, Pognan N, et al. · Br J Clin Pharmacol 2022 · Clinical Trial, Phase I, Multicenter Study
- Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
Felip E, Metro G, Tan DSW, et al. · Lung Cancer 2024 · Multicenter Study, Clinical Trial, Phase II
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.